Minimal Residual Disease in Melanoma

Biology, Detection and Clinical Relevance

With 40 Figures and 45 Tables
Recent results in cancer research; 158

Prof. Dr. med. Uwe Reinhold
Prof. Dr. med. Wolfgang Tilgen

Universitätskliniken des Saarlandes
Haut- und Poliklinik
66421 Homburg/Saar, Germany

ISSN 0080-0015

Library of Congress Cataloging-in-Publication Data

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilm or in any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from Springer-Verlag. Violations are liable for prosecution under the German Copyright Law.

Springer-Verlag Berlin Heidelberg New York
a member of BertelsmannSpringer Science+Business Media GmbH

© Springer-Verlag Berlin · Heidelberg 2001
Printed in Germany

The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Product liability: The publisher cannot guarantee the accuracy of any information about dosage and application contained in this book. In every individual case the user must check such information by consulting the relevant literature.

Production: PRO EDIT GmbH, 69126 Heidelberg, Germany
Typesetting: K+V Fotosatz GmbH, 64743 Beerfelden, Germany

Printed on acid-free paper SPIN 10764787 21/3130göh 5 4 3 2 1 0
I. Biology of Micrometastases and Advances in Methods for Detection

The Biology of Melanoma Micrometastases .................... 3
R.L. Barnhill

Disseminated Tumor Cells:
Diagnosis, Prognostic Relevance, and Phenotyping ............... 14
K. Pantel and M. Otté

Nested Quantitative Real Time PCR for Detection
of Occult Tumor Cells ........................................... 25
N. Max, K. Wolf, B. Spike, E. Thiel, and U. Keilholz

Detection of Micrometastasis Through Tissue-Specific
Gene Expression: Its Promise and Problems .................. 32
R. Jung, K. Soondrum, W. Krüger, and M. Neumaier

Immunobead-Based Detection and Characterization of Circulating
Tumor Cells in Melanoma Patients .......................... 40
Ø. Fodstad, R. Faye, H.K. Høifødt, E. Skovlund,
and S. Aamdal

Rapid Enrichment and Detection of Melanoma Cells from PBMC
by a New Assay Combining Immunomagnetic Cell Sorting
and Immunocytochemical Staining .......................... 51
C. Siewert, M. Herber, N. Hunzelmann, Ø. Fodstad,
S. Miltenyi, M. Assenmacher, and J. Schmitz
II. Detection of Residual Melanoma Cells in the Peripheral Blood and Bone Marrow

Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) Detection of Melanoma-Related Transcripts in the Peripheral Blood and Bone Marrow of Patients with Malignant Melanoma. What Have We Learned? ................................................................. 63
   R. A. Ghossein, S. Bhattacharya, and D. G. Coit

The Clinical Utility of Multimarker RT-PCR in the Detection of Occult Metastasis in Patients with Melanoma ................. 78
   T. Nakayama, and D. S. B. Hoon

Polymerase Chain Reaction in the Detection of Circulating Tumour Cells in Peripheral Blood of Melanoma Patients ........ 93
   B. Schittek, H.-J. Blaheta, U. Ellwanger, and C. Garbe

Facts and Pitfalls in the Detection of Tyrosinase mRNA in the Blood of Melanoma Patients by RT-PCR ...................... 105
   S. Seiter, G. Rappl, W. Tilgen, S. Ugurel, and U. Reinhold

Morphologically Intact Melanoma Cells May Be Detected in Peripheral Blood of Melanoma Patients ....................... 113
   A. Benez, U. Schiebel, and G. Fierlbeck

Prognosis of Metastatic Melanoma: No Correlation of Tyrosinase mRNA in Bone Marrow and Survival Time ............ 118
   V. Waldmann, J. Wacker, M. Deichmann, A. Jäckel, M. Bock,
   and H. Näher

III. Detection of Minimal Residual Disease in Sentinel Nodes

The Predictive Value of the Sentinel Lymph Node in Malignant Melanomas ................................................................. 129

Detection of Micrometastasis in Sentinel Lymph Nodes of Patients with Primary Cutaneous Melanoma ..................... 137
   H.-J. Blaheta, B. Schittek, H. Breuninger, and C. Garbe
IV. Early Recognition and Monitoring by Serological Markers

Monitoring Malignant Melanoma with the S-100B Tumour Marker . 149
J. M. G. Bonfrer and C. M. Korse

Melanoma Inhibitory Activity (MIA), a Serological Marker of Malignant Melanoma .......................... 158
A. K. Bosserhoff, D. Dreau, R. Hein, M. Landthaler,
W. D. Holder, and R. Buettner

Quantification of Melanoma-Associated Molecules in Plasma/Serum of Melanoma Patients .................. 169
A. Hauschild, R. Gläser, and E. Christophers

V. Clinical Relevance of Micrometastases Detection

Molecular Tools in the Detection of Micrometastatic Cancer Cells – Technical Aspects and Clinical Relevance ................. 181
M. von Knebel Doeberitz, J. Weitz, M. Koch, J. Lacroix,
A. Schrödel, and C. Herfarth

The Clinical Relevance of Molecular Staging for Melanoma .......................... 187
S. C. Shivers, W. Li, J. Lin, A. Stall, M. Stafford, J. Messina,
L. F. Glass, and D. S. Reintgen

Clinical Significance of PCR-Positive mRNA Markers in Peripheral Blood and Regional Nodes of Malignant Melanoma Patients .......................... 200
G. Palmieri, M. Pirastu, M. Strazzullo, P. A. Ascierto,
S. M. R. Satriano, M. L. Motti, G. Botti, N. Mozzillo,
G. Castello for the Melanoma Cooperative Group, A. Cossu,
A. Lissia, and F. Tanda

Decrease in Circulating Tumor Cells as an Early Marker of Therapy Effectiveness .......................... 204
J.-C. Bystryn, J. Albrecht, S. R. Reynolds, M. C. Rivas,
R. Oratz, R. L. Shapiro, D. F. Roses, M. N. Harris,
and A. Conrad
VI. Therapeutic Strategies Against Residual Melanoma Cells

Utility of Tests for Circulating Melanoma Cells in Identifying Patients Who Develop Recurrent Melanoma .................................................. 211
   B.J. Curry, K. Myers, and P. Hersey

Active Specific Immunotherapy of Malignant Melanoma and Peptide Mimics of the Human High-Molecular-Weight Melanoma-Associated Antigen ........................................... 231
   S. Ferrone and X. Wang

Autologous Dendritic Cells for Treatment of Advanced Cancer – An Update ................................................................. 236
   D. Schadendorf and F.O. Nestle

A Novel Strategy in the Elimination of Disseminated Melanoma Cells: Chimeric Receptors Endow T Cells with Tumor Specificity ............ 249
   H. Abken, A. Hombach, C. Heuser, and U. Reinhold

Subject Index ......................................................................................................................................................... 265